DC-P-234

DC-P-234 is an investigational antibody-drug conjugate (ADC) currently in preclinical development by Tubulis for the treatment of solid tumors. The candidate is characterized by the incorporation of a novel cytotoxic payload, which is a core component of Tubulis's approach to enhancing the therapeutic index and efficacy of ADC therapies. While the specific biological target of the antibody remains undisclosed, the drug leverages proprietary conjugation technologies designed to improve conjugate stability and ensure the selective delivery of the potent payload to tumor cells while minimizing off-target toxicity. DC-P-234 represents part of a growing pipeline of next-generation ADCs aimed at overcoming the limitations of traditional ADC platforms through innovative linker-payload chemistry.